1 / 18

Safety in Analgesia Trials. Arthritis Advisory Committee Meeting ... Efficacy in OA at 100 and 200 mg BID. Efficacy in RA at 200 and 400 mg BID. No efficacy ...

Kelvin_Ajay
Download Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Safety in Analgesia TrialsArthritis Advisory Committee Meeting July 29-30, 2002 M. Lourdes Villalba, M.D. FDA/CDER/DAAODP

  2. Exposure Requirements • Chronic use - ICH Guidelines (E1A) • Minimum: • 300-600 patients for 6 months • 100 patients for one year • 1500 (total exposure) • Larger and/or longer term safety database may be needed • Specific safety concerns • Need to make risk/benefit decisions

  3. Exposure Requirements “Dose-creep” PhenomenonCelebrex® NDA • Randomized Controlled Trials • Efficacy in OA at 100 and 200 mg BID • Efficacy in RA at 200 and 400 mg BID • No efficacy advantage of the higher doses • Open label • Most patients (~70%) increased dose • Moved to a dose twice as high (200 mg BID for OA and 400 mg BID for RA)

  4. Exposure RequirementsChronic Use • Adequate assessment of chronic safety • Minimum ICH guidelines at the highest labeled dose • Specific safety concerns • Special populations

  5. Exposure Requirements • Acute or short-term use • As much as if it were intended for chronic use • Use beyond recommended duration • Vioxx® 50 mg (rofecoxib) • Duract® (bromfenac sodium)

  6. Acute or Short-Term UseVioxx® 50 mg Usage Data* • Number of total drug appearances (all dose strengths): 12,853,000 50 mg strength (acute, 2X chronic): 652,000 (5 % of total)  30 days 140,000 (21 %) * (IMS Health data, 5/99 to 9/00)

  7. Acute or Short Term UseDuract®(Bromfenac) • NSAID approved July 1997 • Sponsor voluntary withdrawal June 1998 due to reports of hepatic failure • NDA originally proposed • Indications: acute pain, dysmenorrhea & OA • Dose: 25-50 mg q 6-8 hrs. up to 200 mg/day • At filing, insufficient exposure for OA indication • OA indication withdrawn • Chronic safety data submitted to NDA

  8. Patients Exposed to Bromfenac in NDA • Acute pain 1071 Multiple dose (up to 1wk) 384 • Dysmenorrhea 245 • Chronic (OA & RA) 926 Total 2242

  9. Chronic Exposure to Bromfenac in NDA Dose (mg/d) >30* >90* >180* >360* Any dose 799 578 474 193 200-225 164 124 105 24 150-199 102 81 68 50 76-149 453 349 283 108 75 or less 80 24 18 11 Safety update Any dose 1195 926 734 247 * Days of exposure

  10. Bromfenac NDA-Chronic Studies • OA (N= 551) & RA (N= 316) • Fixed doses 50 to 200 mg/d • Placebo-controlled, 4-6 weeks Active-controlled, 4 weeks to 1 year (ASA, naproxen, ibuprofen, diclofenac) • Open label experience up to 4 years (some up to 225 mg/d) N= patients randomized to bromfenac

  11. Bromfenac NDA • Acute pain studies: efficacy and safety at the 25 and 50 mg single dose • Safety data from short-term multiple dose • Absolutely no safety concerns • Chronic studies in OA and RA at 25 and 50 mg BID, TID and QID • “Flag” for hepatotoxicity

  12. Bromfenac NDA - Liver Signal • LFT elevation: mild 15% (< 3X ULN) and clinically significant 2.8% *( 3X ULN or higher) • Dose-related • Most reversible after drug discontinuation • Majority within 90 days • Earliest occurred around day 30 * NSAID template: LFT elevation in clinical trials mild ~ 15% & clinically significant~ 1%.

  13. Duract® Approved Label WARNINGS • Risk of hepatic effects: • 2.8 % LFT elevation 3 x ULN & higher at some point (0.4% in short term trials) • 0.4% LFT elevations 8 x ULN & higher in in longer term trials • Short-term use for pain should be < 10 days • Because of risk of hepatic toxicity, if longer therapy is needed, LFT’s should be monitored after 4 weeks • Maximum daily dose limited to 150 mg/day • Removal of any references to treatment of OA, chronic pain and dysmenorrhea

  14. Duract®Post-marketing Reports • Liver toxicity including hepatic failure, need for liver transplantation and death • Most within labeled doses • Most exposed for longer than 10 days (2 to 8 months)

  15. Acute Pain - Safety Issues • Short-term safety is insufficient • Drug development should address potential safety concerns (dose-creep, use for longer than intended, potential for abuse) • Ideally, for short-term indication, unless contraindicated based on safety, formal efficacy studies needed in chronic setting

  16. Bromfenac NDA- Liver Signal • Notable LFT elevation in 23 / 830 patients (bromfenac 75 mg/d or more in chronic studies) • 19 ALT x 3-8 ULN 2.8% * • 4 ALT x >8 ULN • 2 at 50 mg/d; 5 at 100 mg/d; 10 at 150 mg/d • Earliest occurred around day 30 * Similar to AST’s in Diclofenac NDA. NSAID template: LFT elevation in clinical trials mild ~ 15% & notable ~ 1%

  17. Exposure RequirementsICH E1A • Larger or longer-term safety • Late AE or AE that increase in severity or frequency over time • Need to quantitate rate of expected specific low-frequency AE • To make risk/benefit decisions (small effect) • To detect prespecified increases over baseline morbidity or mortality

More Related